Using trilaciclib to prevent bone marrow suppression in esophageal cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study collects clinical data from patients with esophageal squamous cell carcinoma undergoing concurrent chemoradiotherapy. Patients are divided into two groups: one receiving trilaciclib before chemotherapy and a control group not receiving it. The study employs propensity score matching to ensure balanced baseline characteristics between the groups, allowing for a fair comparison of bone marrow suppression rates and other adverse events. This is the first investigation into the efficacy and safety of trilaciclib for this purpose in esophageal cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age ≥18 years;
* pathological diagnosis of esophageal squamous cell carcinoma;
* failure to undergo surgical treatment;
* completion of definitive chemoradiotherapy or chemoradiotherapy combined with immunotherapy.

Exclusion Criteria:

* history of other malignant tumors;
* difficulty in follow-up;
* insufficient clinical information.

Where it's running

• The First Affiliated Hospital of Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Principal investigator: Xiao L Ge, PHD — The First Affiliated Hospital with Nanjing Medical University
• Study coordinator: Xiaolin Ge, PHD
• Email: doctorsxl@163.com
• Phone: 86+83714511

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Becotatug Vedotin with Immunotherapy and Radiotherapy in ESCC after first line

  This trial tests whether adding becotatug vedotin to an immune checkpoint inhibitor and targeted radiotherapy helps people with advanced ESCC after prior treatment.

  Recruiting Phase 2 The First Affiliated Hospital of Bengbu Medical University · Bengbu, Anhui · NCT07892833

• Lymphatic-sparing short-course radiotherapy with chemo-immunotherapy before surgery for locally advanced ESCC

  This study tests whether a short course of targeted radiotherapy combined with camrelizumab and nab-paclitaxel/carboplatin can shrink locally advanced esophageal squamous cell carcinoma enough for surgical removal.

  Recruiting Phase 2 Sixth Affiliated Hospital, Sun Yat-sen University · Guanzhou, Guangdong · NCT07808853

• Anlotinib plus Bemocizumab as neoadjuvant therapy for ESCC

  This trial tests whether giving anlotinib with bemocizumab before surgery can improve how completely the tumor is removed and prevent recurrence in people with resectable esophageal squamous cell carcinoma.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07627347

• Blood test combining cell-free and exosomal microRNAs for early detection of esophageal squamous cell carcinoma

  This project will try a blood test that measures cell-free and exosomal microRNAs to find early esophageal squamous cell carcinoma in adults using plasma or serum samples.

  Recruiting City of Hope Medical Center · Monrovia, California · NCT07266363

• NRM-823 for advanced or metastatic refractory solid tumors

  This trial tests whether NRM-823 is safe and can help people with advanced or metastatic head and neck, esophageal, gastric, or related cancers.

  Recruiting at 18 sites Phase 1 Normunity AccelCo, Inc. · Denver, Colorado and 17 other locations · NCT07182149

• ALX2004 for advanced or metastatic EGFR-expressing solid tumors

  This trial will test ALX2004, an antibody-drug conjugate that targets EGFR, in people with advanced or metastatic non-small cell lung, head and neck, esophageal, or colorectal cancer to see if it is safe and shows tumor activity.

  Recruiting at 11 sites Phase 1 ALX Oncology Inc. · La Jolla, California and 11 other locations · NCT07085091

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.